Skip to main content
Log in

Transport of Human Recombinant Brain-Derived Neurotrophic Factor (BDNF) Through the Rat Blood−Brain Barrier in Vivo Using Vector-Mediated Peptide Drug Delivery

  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Abstract

The blood–brain barrier (BBB) transport of brain-derived neurotrophic factor (BDNF) in anesthetized rats was examined in the present studies using vector-mediated peptide drug delivery. Following tritiation, the BDNF was biotinylated via a disulfide linker and was coupled to a covalent conjugate of neutral avidin (NLA), which binds the biotinylated peptide with a high affinity, and the murine OX26 monoclonal antibody to the rat transferrin receptor. Owing to the abundance of transferrin receptors on brain capillary endothelium, the OX26 monoclonal antibody undergoes receptor-mediated transcytosis through the BBB, and the NLA–OX26 conjugate transports biotinylated peptide therapeutics through the BBB. The present studies show that while unconjugated BDNF was not transported through the BBB in vivo, the conjugation of biotinylated BDNF to the NLA–OX26 vector resulted in a marked increase in the brain delivery of BDNF, as defined by measurements of the percentage of the injected dose (ID) delivered per gram of brain. Although BDNF was not transported through the BBB in vivo, this cationic peptide was avidly bound by isolated human brain capillaries via a low-affinity, high-capacity system that was inhibited by protamine and by serum protein binding of BDNF. In conclusion, these studies show that the delivery of unconjugated BDNF to brain is nil owing to the combined effects of negligible BBB transport and rapid systemic clearance of intravenous administered BDNF. The brain delivery of BDNF may be augmented by conjugation of BDNF to BBB drug delivery vectors, such as the NLA–OX26 conjugate.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. W. C. Mobley, A. C. Server, D. N. Ishii, R. J. Riopelle, and E. M. Shooter. Nerve growth factor. N. Engl. J. Med. 297:1096–1104 (1977).

    Google Scholar 

  2. G. D. Yancopoulos, P. C. Maisonpierre, N. Y. Ip, T. H. Aldrich, L. Belluscio, T. G. Boulton, M. H. Cobb, S. P. Squinto, and M. E. Furth. Neurotrophic factors, their receptors, and the signal transduction pathways they activate. Cold Spring Harbor Symp. Quant. Biol. 55:371–379 (1990).

    Google Scholar 

  3. R. F. Alderson, A. L. Alterman, Y.-A. Barde, and R. M. Lindsay. Brain-derived neurotrophic factor increases survival and differentiated functions of rat septal cholinergic neurons in culture. Neuron 5:297–306 (1990).

    Article  CAS  PubMed  Google Scholar 

  4. B. Knüsel, J. W. Winslow, A. Rosenthal, L. E. Burton, D. P. Seid, K. Nikolics, and F. Hefti. Promotion of central cholinergic and dopaminergic neuron differentiation by brain-derived neurotrophic factor but not neurotrophin 3. Proc. Natl. Acad. Sci. USA 88:961–965 (1991).

    Google Scholar 

  5. C. Hyman, M. Hofer, Y.-A. Barde, M. Juhasz, G. D. Yancopoulos, S. P. Squinto, and R. M. Lindsay. BDNF is a neurotrophic factor for dopaminergic neurons of thesubstantia nigra. Nature 350:320–232 (1991).

    Google Scholar 

  6. M. B. Spina, S. P. Squinto, J. Miller, R. M. Lindsay, and C. Hyman. Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenylpyridinium ion toxicity: involvement of the glutathione system. J. Neurochem. 59:99–106 (1992).

    Google Scholar 

  7. C. A. Altar, C. B. Boylan, C. Jackson, S. Hershenson, J. Miller, S. J. Wiegand, R. M. Lindsay, and C. Hyman. Brain-derived neurotrophic factor augments rotational behavior and nigrostriatal dopamine turnover in vivo. Proc. Natl. Acad. USA 89:11347–11351 (1992).

    Google Scholar 

  8. M. M. LaVail, K. Unoki, D. Yasumura, M. T. Matthes, G. D. Yancopoulos, and R. H. Steinberg. Multiple growth factors, cytokines, and neurotrophins rescue photoreceptors from the damaging effects of constant light. Proc. Natl. Acad. Sci. USA 89:11249–11253 (1992).

    Google Scholar 

  9. O. Lindvall, P. Ernfors, J. Bengzon, Z. Kokaia, M.-L. Smith, B. K. Siesjö, and H. Persson. Differential regulation of mRNAs for nerve growth factor, brain-derived neurotrophic factor, and neurotrophin 3 in the adult rat brain following cerebral ischemia and hypoglycemic coma. Proc. Natl. Acad. Sci. USA 89:648–652 (1992).

    Google Scholar 

  10. H. S. Phillips, J. M. Hains, G. R. Laramee, A. Rosenthal, and J. W. Winslow. Widespread expression of BDNF but not NT3 by target areas of basal forebrain cholinergic neurons. Science 250:290–294 (1990).

    Google Scholar 

  11. W. M. Pardridge. Peptide Drug Delivery to the Brain, Raven Press, New York, 1991, pp. 1–357.

    Google Scholar 

  12. P. M. Friden, L. R. Walus, P. Watson, S. R. Doctrow, J. W. Kozarich, C. Backman, H. Bergman, B. Hoffer, F. Bloom, and A.-C. Granholm. Blood-brain barrier penetration and in vivo activity of an NGF conjugate. Science 259:373–377 (1993).

    Google Scholar 

  13. T. Yoshikawa and W. M. Pardridge. Biotin delivery to brain with a covalent conjugate of avidin and a monoclonal antibody to the transferrin receptor. J. Pharmacol. Exp. Ther. 263:897–903 (1992).

    Google Scholar 

  14. Y.-S. Kang and W. M. Pardridge. Use of neutral-avidin improves pharmacokinetics and brain delivery of biotin bound to an avidin-monoclonal antibody conjugate. J. Pharmacol. Exp. Ther. 269:344–350 (1994).

    Google Scholar 

  15. W. M. Pardridge, J. L. Buciak, and T. Yoshikawa. Transport of recombinant CD4 through the rat blood-brain barrier. J. Pharmacol. Exp. Ther. 261:1175–1180 (1992).

    Google Scholar 

  16. U. Bickel, T. Yoshikawa, E. M. Landaw, K. F. Faull, and W. M. Pardridge. Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery. Proc. Natl. Acad. Sci. 90:2618–2622 (1993).

    Google Scholar 

  17. W. M. Pardridge, J. Eisenberg, and J. Yang. Human blood-brain barrier insulin receptor. J. Neurochem. 44:1771–1778 (1985).

    Google Scholar 

  18. M. Gibaldi and D. Perrier. Pharmacokinetics, Marcel Dekker, New York (1982).

    Google Scholar 

  19. J. Leibrock, F. Lottspeich, A. Hohn, M. Hofer, B. Hengerer, P. Masiakowski, H. Thoenen, and Y.-A. Barde. Molecular cloning and expression of brain-derived neurotrophic factor. Nature 341:149–152 (1989).

    Article  CAS  PubMed  Google Scholar 

  20. K. R. Jones and L. F. Reichardt. Molecular cloning of a human gene that is a member of the nerve growth factor family. Proc. Natl. Acad. Sci. USA 87:8060–8064 (1990).

    Google Scholar 

  21. A. Rosenthal, D. V. Goeddel, T. Nguyen, E. Martin, L. E. Burton, A. Shih, G. R. Laramee, F. Wurm, A. Mason, K. Nikolics, and J. W. Winslow. Primary structure and biological activity of human brain-derived neurotrophic factor. Endocrinology 129:1289–1294 (1991).

    Google Scholar 

  22. A. W. Vorbrodt. Ultracytochemical characterization of anionic sites in the wall of brain capillaries. J. Neurocytol. 18:359–368 (1989).

    Google Scholar 

  23. W. M. Pardridge, J. L. Buciak, Y.-S. Kang, and R. J. Boado. Protamine-mediated transport of albumin into brain and other organs in the rat. Binding and endocytosis of protamine-albumin complex by microvascular endothelium. J. Clin. Invest. 92: 2224–2229 (1993).

    Google Scholar 

  24. M. A. Lupo, W. T. Cefalu, and W. M. Pardridge. Kinetics of lactate transport into rat liver in vivo. Metabolism 39:374–378 (1990).

    Google Scholar 

  25. Y.-S. Kang, U. Bickel, and W. M. Pardridge. Pharmacokinetics and saturable blood-brain barrier transport of biotin bound to a conjugate of avidin and a monoclonal antibody to the transferrin receptor. Drug Metabol. Disp. 22:99–105 (1994).

    Google Scholar 

  26. U. Bickel and W. M. Pardridge. Rapid cleavage of disulfide-based chimeric peptides by rat brain in vivo. Faseb J., in press (1994).

  27. M. B. Rosenberg, E. Hawrot, and X. O. Breakefield. Receptor binding activities of biotinylated derivatives of β-nerve growth factor. J. Neurochem. 46:641–648 (1986).

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pardridge, W.M., Kang, YS. & Buciak, J.L. Transport of Human Recombinant Brain-Derived Neurotrophic Factor (BDNF) Through the Rat Blood−Brain Barrier in Vivo Using Vector-Mediated Peptide Drug Delivery. Pharm Res 11, 738–746 (1994). https://doi.org/10.1023/A:1018940732550

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1018940732550

Navigation